Compare Deutsche Bank AG (DB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Novo Nordisk A/S — how do they compare? Deutsche Bank AG trades at $35.97 (market cap $68.51B), while Novo Nordisk A/S trades at $49.1 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Deutsche Bank AG's market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| DB | NVO | |
|---|---|---|
Market Cap | $68.51B | $214.94B |
Sector | Financials | Health |
52-Week High | $40.33 | $71.70 |
52-Week Low | $28.37 | $35.29 |
Dividend Yield | 3.26% | 3.67% |
Enterprise Value | — | $233.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $35.24, down 1.48% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows attractive valuation metrics with a P/E of 9.79 and P/B of 0.76. Recent quarterly earnings have consistently beaten expectations, and the company announced a $1.00 dividend for H1-26. However, 2024 cash flow was negative $33.10 billion, though it improved to a positive $7.6 billion in 2025.
The outlook is mixed; strong profitability and earnings beats support upside, but regulatory scrutiny and volatile cash flows pose risks. Analyst consensus is cautious with 57.58% hold ratings. The stock's low valuation may appeal to value investors, yet headline risks from recent legal searches require monitoring.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
